Back to search
PIK3CA-related Overgrowth Spectrum
Clinical trial pipeline · Data from ClinicalTrials.gov
See which PIK3CA-related Overgrowth Spectrum trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which PIK3CA-related Overgrowth Spectrum trials you may qualify forThis study will examine rare congenital disorders that involve malformations and abnormal growth. It will focus on patients with Proteus syndrome, whose physica…
Recent studies have demonstrated that growth of vascular malformations can be driven by genetic variants in one of 2 signalling pathways. Targeted drugs specifi…
This is a 3-part Phase 2 randomized study evaluating the safety and efficacy of the mutant-selective PI3Kα inhibitor, RLY-2608, in adults and children with PIK3…
This study is designed to demonstrate the efficacy and assess safety and tolerability of oral daily alpelisib in participants with PIK3CA-related overgrowth spe…
This study is a multi-center, open-label, single arm, phase I/II study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of CYH33…
This is a prospective Phase II multi-center study with an initial 16-week, randomized, double-blind, placebo-controlled period, followed by two extension period…
The purpose of this registration is to list Managed Access Programs (MAPs) related to BYL719, Alpelisib
This is a prospective interventional Phase II multi center study, open label, preceded by a retrospective non-interventional period, to assess the long-term saf…